公开(公告)号：US20180208552A1

公开(公告)日：2018-07-26

申请号：US15576345

申请日：2016-05-26

申请人： KYORIN PHARMACEUTICAL CO., LTD.

发明人： Hiroyasu TAKAHASHI ,  Hiroyuki WATANABE ,  Kiyoshi FUJII ,  Mitsuhito SHIBASAKI ,  Mikako KAWASHIMA ,  Megumi KAMIYA ,  Kohei OHATA

IPC分类号： C07C275/30 ,  C07C275/42 ,  C07C275/50 ,  C07D231/12 ,  C07D285/08 ,  C07D285/135 ,  C07D271/113 ,  C07D271/07 ,  C07D239/36 ,  A61P29/00 ,  A61P35/00 ,  A61P31/18

CPC分类号： C07C275/30 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  C07B2200/07 ,  C07C275/42 ,  C07C275/50 ,  C07C311/51 ,  C07C317/32 ,  C07C317/40 ,  C07C2601/02 ,  C07D213/61 ,  C07D231/12 ,  C07D239/36 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D263/34 ,  C07D271/06 ,  C07D271/07 ,  C07D271/10 ,  C07D271/113 ,  C07D273/04 ,  C07D277/28 ,  C07D285/08 ,  C07D285/12 ,  C07D285/135 ,  C07D307/79 ,  C07D311/58 ,  C07D333/16 ,  C07D333/28 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

摘要： The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.